The protocol for expression of proteins makes use of expression vectors, competent cells, reagents, instrument, and services. The reagents are the estimated to hold the largest share due to large volume used in the bio-experiments. The significant growth in the protein expression market is primarily due to the increasing funds from government and non-government organization for protein research, the soaring prevalence of chronic diseases, rising life science industry.
Request for Free Sample Copy of this Research Report at https://www.vynzresearch.com/healthcare/protein-expression-market/request-sample
Pharmaceutical and biotechnology companies are the largest end-user in the protein expression market. The category’s largest contribution is due to the large production of recombinant proteins for therapeutics, and the growing advancement in technology with respect to protein research. Further, other end users to the protein expression market include academic research institutes, contract research organizations (CROs), others industries such as food processing, brewery, leather, paper, chemical, and cosmetic industries. The CROs are projected to witness high demand and register the fastest CAGR of 13.7% during the forecast period.
Geographically, North America is the largest market for protein expression products and services, globally. The largest contribution of the region is due to the adaptation of technologically advanced products, and the increasing government and non-government funds for protein research.
The major player in the global protein expression market includes New England Biolabs, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Takara Bio Inc., Lonza Group Ltd., Merck KGaA, Promega Corporation, Genscript Biotech Corporation, Agilent Technologies Inc., and Bio-Rad Laboratories, Inc.
Read Full Research Report Description at https://www.vynzresearch.com/healthcare/protein-expression-market
The market players are launching new and technologically advanced products and services to maintain their competency and market share. For instance, in March 2018, Aragen Bioscience, Inc. announced the expansion of its RapTr cell line development services to be included in CHO-GS cell lines. The addition of suite protein expression and analytical services will provide flexibility in the development of cell lines and the generation of high-quality proteins.
Source: VynZ Research